Torrent Pharmaceuticals Limited

NSE:TORNTPHARM.NS

3351.9 (INR) • At close September 19, 2024
Overview | Financials

Numbers are in millions (except for per share data and ratios) INR.

2024 Q12023 Q42023 Q32023 Q22023 Q12022 Q42022 Q32022 Q22022 Q12021 Q42021 Q32021 Q22021 Q12020 Q42020 Q32020 Q22020 Q12019 Q42019 Q32019 Q22019 Q12018 Q42018 Q32018 Q22018 Q12017 Q42017 Q32017 Q22017 Q12016 Q42016 Q32016 Q22016 Q12015 Q42015 Q32015 Q22015 Q12014 Q42014 Q32014 Q22014 Q12013 Q42013 Q32013 Q22013 Q12012 Q42012 Q32012 Q22012 Q12011 Q42011 Q3
Revenue 28,59027,45026,91026,28025,48024,52024,59022,61022,92021,03820,92021,03021,20019,152.319,72019,85020,14019,120.119,24019,68019,76018,218.419,48018,58018,34016,80014,48014,01013,48013,81014,13014,06015,07014,77015,15016,55018,86011,27811,56012,03010,92012,0339,9009,3609,0307,971.17,686.37,4707,3606,540.0066,734.7
Cost of Revenue 14,41013,6806,9706,6006,5007,0407,3006,4106,6007,164.76,3805,9505,8805,8435,6205,5405,3506,135.25,4205,3805,5906,356.75,8005,4805,5804,6303,9204,1804,0104,9004,6404,0104,3704,1103,7203,7604,1804,205.63,7203,8103,0103,774.83,1803,0103,0402,843.22,467.12,1702,2003,410.3932,222.8
Gross Profit 14,18013,77019,94019,68018,98017,48017,29016,20016,32013,873.314,54015,08015,32013,309.314,10014,31014,79012,984.913,82014,30014,17011,861.713,68013,10012,76012,17010,5609,8309,4708,9109,49010,05010,70010,66011,43012,79014,6807,072.47,8408,2207,9108,258.26,7206,3505,9905,127.95,219.25,3005,1603,129.6134,511.9
Gross Profit Ratio 0.4960.5020.7410.7490.7450.7130.7030.7160.7120.6590.6950.7170.7230.6950.7150.7210.7340.6790.7180.7270.7170.6510.7020.7050.6960.7240.7290.7020.7030.6450.6720.7150.710.7220.7540.7730.7780.6270.6780.6830.7240.6860.6790.6780.6630.6430.6790.710.7010.4790.67
Reseach & Development Expenses 1,3501,3901,2701,3201,2901,5001,2301,2101,2205,1601,2301,3001,2501,4801,1201,1901,0801,1801,1001,3001,3601,4001,3501,3601,2804,6001,1601,0701,0101,3609501,1109102,4600001,9100001,7000001,25000000
General & Administrative Expenses 000000000000000000000000000000000000000001,619.50001,361.400000
Selling & Marketing Expenses 000000000000000000000000000000000000000004,4840003,847.100000
SG&A 5,7605,5805,4305,4004,9904,6904,9104,5604,2003,862.93,8803,8903,5903,606.93,6303,6303,7303,491.23,5403,5803,8103,467.93,6803,4303,4603,172.52,7202,8302,6302,494.12,3302,5902,5202,163.52,0602,1002,1002,701.91,9902,2401,84010,440.41,7901,8201,7208,5311,537.80000
Other Expenses 240310-33026034090-100160300-1,292.7480510400-139.7806040-1,056530340200-375.4301002709,6207407801,0501,0406,5607,0106,7502405,4005,5205,5107,908.25,3305,3304,1804,393.24,6804,6804,0403,332.53,722.73,8403,6602,529.5343,369
Operating Expenses 7,1106,97013,38013,44012,98012,17011,98011,04010,7509,929.910,83010,16010,2009,125.69,7009,6109,7909,156.410,05010,52010,3608,7059,6309,8909,4909,6207,9107,3807,3006,9306,5607,0106,7506,4205,4005,5205,5107,908.25,3305,3304,1804,393.24,6804,6804,0403,332.53,722.73,8403,6602,529.5343,369
Operating Income 7,0706,8006,2306,5006,0005,4005,2105,3205,5703,943.43,7104,9205,1204,183.74,4004,7005,0003,828.53,7703,7803,8103,156.74,0503,2103,2702,5502,6502,4502,1701,9802,9303,0403,9504,2406,0307,2709,170-835.82,5102,8903,7303,8652,0401,6701,9501,795.41,496.51,4601,500600.0791,142.9
Operating Income Ratio 0.2470.2480.2320.2470.2350.220.2120.2350.2430.1870.1770.2340.2420.2180.2230.2370.2480.20.1960.1920.1930.1730.2080.1730.1780.1520.1830.1750.1610.1430.2070.2160.2620.2870.3980.4390.486-0.0740.2170.240.3420.3210.2060.1780.2160.2250.1950.1950.2040.0920.17
Total Other Income Expenses Net -510-49080-910-690-1,070-1,020-690-250-4,814.3-140-200-280-351.1-830-860-980-902.8-580-820-1,020-4,660.1-1,300-1,160-950-1,210-60270490460-480-510-490-140-42050-5802,383.9-500-540-240-695.2-160-150-80-206.7-67.3-70-100-586.161-103.2
Income Before Tax 6,5606,3106,3105,5905,3104,3304,1904,6305,320-870.93,5704,7204,8403,832.63,5703,8404,0202,925.73,1902,9602,790-1,503.42,7502,0502,3201,3402,5902,7202,6602,4402,4502,5303,4604,1005,6107,3208,5901,548.12,0102,3503,4903,169.81,8801,5201,8701,588.71,429.21,3901,40013.9181,039.7
Income Before Tax Ratio 0.2290.230.2340.2130.2080.1770.170.2050.232-0.0410.1710.2240.2280.20.1810.1930.20.1530.1660.150.141-0.0830.1410.110.1260.080.1790.1940.1970.1770.1730.180.230.2780.370.4420.4550.1370.1740.1950.320.2630.190.1620.2070.1990.1860.1860.190.0020.154
Income Tax Expense 1,9901,8201,8801,7301,5301,3701,3601,5101,780307.31,0801,5601,540593.8600740810-211.568052063013.5290260690-9402,0106807803801604605401,2607801,6404,100248.4340370930730.7300390380475.3308.631037023.651200.6
Net Income 4,5704,493.84,4303,8603,7802,962.32,9203,1203,540-1,178.22,4903,1603,3003,238.82,9703,1003,2103,137.22,5102,4402,160-1,517.22,4601,7901,6302,2805802,0401,8802,0602,2902,0702,9202,8404,8305,6804,4901,299.41,6701,9802,5602,438.81,5801,1301,4901,113.31,123.31,0701,020-16.545831.8
Net Income Ratio 0.160.1640.1650.1470.1480.1210.1190.1380.154-0.0560.1190.150.1560.1690.1510.1560.1590.1640.130.1240.109-0.0830.1260.0960.0890.1360.040.1460.1390.1490.1620.1470.1940.1920.3190.3430.2380.1150.1440.1650.2340.2030.160.1210.1650.140.1460.1430.139-0.0030.124
EPS 13.513.2713.0911.4111.178.488.369.2210.46-3.487.379.329.779.558.769.169.499.277.397.246.37-4.497.255.294.836.781.696.045.546.096.746.138.648.418.615.0119.23.844.935.857.567.214.673.324.413.293.323.173.01-0.0492.46
EPS Diluted 13.513.2713.0911.4111.178.488.369.2210.45-3.487.379.329.779.558.769.169.499.277.397.246.37-4.487.255.294.836.781.696.045.546.096.746.138.648.418.615.0119.23.844.935.857.567.214.673.324.413.293.273.173.01-0.0492.46
EBITDA 9,0408,8308,3608,5108,2507,3607,1406,9507,4201,267.75,8607,1107,1706,187.36,1506,4106,6505,311.15,9305,7505,6101,261.55,6404,8305,0404,0604,3304,0704,0203,9903,6603,7304,6305,1106,6407,8809,7602,424.53,0503,4503,9403,352.22,2501,8902,1602,2321,700.71,6601,7001,086.0921,339.9
EBITDA Ratio 0.3160.3220.3110.3240.3240.30.290.3070.3240.060.280.3380.3380.3230.3120.3230.330.2780.3080.2920.2840.0690.290.260.2750.2420.2990.2910.2980.2890.2590.2650.3070.3460.4380.4760.5170.2150.2640.2870.3610.2790.2270.2020.2390.280.2210.2220.2310.1660.199